At a glance
- Originator GlaxoSmithKline
- Class Small molecules
- Mechanism of Action Beta 3 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Diabetes mellitus; Obesity
Most Recent Events
- 13 Aug 2003 No development reported - Preclinical for Diabetes mellitus in USA (unspecified route)
- 13 Aug 2003 No development reported - Preclinical for Obesity in USA (unspecified route)
- 27 Apr 2001 Preclinical development for Diabetes mellitus in USA (Unknown route)